BioReference Health (clinical diagnostics and reproductive & women's health, outside NY/NJ)
→
LabCorp
Asset Acquisition · Cash · LH · announced Mar 28, 2024
Announced
Mar 28, 2024
Closed
Sep 16, 2024
Economics
Cash
Approximately $237.5M in cash per OPKO 8-K Item 1.01 (agreement) and Item 2.01 (completion), subject to adjustments set forth in the Asset Purchase Agreement dated Mar 27, 2024; no earnout disclosed. Select-asset purchase, not a whole-company acquisition: clinical diagnostics and reproductive and women's health testing outside New York and New Jersey; oncology, urology and all New York and New Jersey operations excluded. Acquired assets generated approximately $100M annual revenue per the Labcorp release.
Target
BioReference Health (clinical diagnostics and reproductive & women's health, outside NY/NJ)
Diagnostics · Diagnostic / genomic
HQ Elmwood Park, NJ
BioReference Health laboratory testing business focused on clinical diagnostics and reproductive and women's health in the US outside New York and New Jersey, including patient service centers, customer contracts and operating assets (approximately $100M annual revenue); divested by OPKO Health subsidiary BioReference Health to Labcorp, which excluded oncology, urology and NY/NJ operations
- SEC EDGAR - OPKO Health 8-K Item 1.01 (Mar 28, 2024; Asset Purchase Agreement dated Mar 27, 2024) https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/opk20240311_8k.htm
- SEC EDGAR - OPKO Health 8-K Item 2.01 (Sep 16, 2024; completed) https://www.sec.gov/Archives/edgar/data/944809/000143774924029310/opk20240903_8k.htm
- Labcorp press release via PR Newswire (Mar 28, 2024; About BioReference Health: "Headquartered in Elmwood Park, New Jersey") https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-acquisition-select-assets-bioreference-healths
Acquirer
LabCorp (LH)
Diagnostics
HQ Burlington, NC
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Labcorp acquires BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproductive and women's health outside New York and New Jersey, including patient service centers, customer contracts and operating assets, to enhance its laboratory services network and expand access to its clinical laboratory services
Evidence ladder
Primary (regulatory / filing)
SEC EDGAR 8-K Item 1.01 (OPKO Health, Mar 28, 2024) https://www.sec.gov/Archives/edgar/data/944809/000143774924009695/opk20240311_8k.htm
Open sourcePrimary (regulatory / filing)
SEC EDGAR 8-K Item 2.01 (OPKO Health, Sep 16, 2024 — completed) https://www.sec.gov/Archives/edgar/data/944809/000143774924029310/opk20240903_8k.htm
Open sourceSecondary (press / IR)
Labcorp press release (Mar 28, 2024) https://ir.labcorp.com/news-releases/news-release-details/labcorp-announces-acquisition-select-assets-bioreference-healths
Open sourceSecondary (press / IR)
Labcorp press release (Sep 16, 2024 — completed) https://ir.labcorp.com/news-releases/news-release-details/labcorp-completes-acquisition-select-assets-bioreference-healths
Open sourceTertiary (trade / analyst)
MedTech Dive coverage (Mar 29, 2024) https://www.medtechdive.com/news/labcorp-buys-bioreference-reproductive-women-health-assets/711713/
Open source
Limitations
- Approximately $237.5M in cash per OPKO 8-K Item 1.01 (agreement) and Item 2.01 (completion), subject to adjustments set forth in the Asset Purchase Agreement dated Mar 27, 2024; no earnout disclosed. Select-asset purchase, not a whole-company acquisition: clinical diagnostics and reproductive and women's health testing outside New York and New Jersey; oncology, urology and all New York and New Jersey operations excluded. Acquired assets generated approximately $100M annual revenue per the Labcorp release.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
| Why included | ||||
|---|---|---|---|---|
| BioReference Health (clinical, women's health, urology and 4Kscore assets) | LabCorp | Oct 15, 2026 | same evidence class · same acquirer |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Vs this deal | ||||
|---|---|---|---|---|
| Invitae Reproductive Health | Natera | Jan 22, 2024 |
Other verified deals by LabCorp
Acquirer program history not already listed as a valuation peer or adjacency row.
| Sector | ||||
|---|---|---|---|---|
| Ovia Health | LabCorp | Aug 12, 2021 | Undisclosed | Maternal Health |
| Sequenom | LabCorp | Jul 27, 2016 | Diagnostics |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — BioReference Health (clinical diagnostics and reproductive & women's health, outside NY/NJ) (Diagnostics). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 5 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.